secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001104659-24-115351
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute Q1 FY2025 net loss $15.4M; cash $117.8M; Phase 3 on track
------------------------------------------------------------------

- Net loss $15.4M vs $14.5M YoY; R&D $12.8M, G&A $4.2M.
- Cash, equivalents, marketable securities $117.8M (Sep 30) vs $127.1M (Jun 30).
- Phase 3 sunRIZE congenital HI enrollment on track; U.S. enrollment expected early 2025.
- Tumor HI Phase 3 enrollment expected H1 2025; topline results H2 2026.
- Topline sunRIZE results expected in second half of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924115351/0001104659-24-115351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924115351/tm2427368d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-115351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer